

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent
PC7180A

IN RE APPLICATION OF:
JOHN A LOWE, III, ET AL.

PATENT NO.: 4,831,031

ISSUED: MAY 16, 1989

FOR: ARYL PIPERAZINYLYL-(C₂ OR C₄)
ALKYLENE HETEROCYCLIC COMPOUNDS
HAVING NEUROLEPTIC ACTIVITY

CERTIFICATE

MAR 05 2001

OF CORRECTION

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

REQUEST FOR CERTIFICATE OF CORRECTION

PFIZER INC., assignee of 100% interest on the above-identified patent, requests issuance of a Certificate of Correction, pursuant to 37 C.F.R. §1.322, in connection with the above-identified patent. The error to be corrected is set forth as described in a Form PTO-1050, which is attached hereto in duplicate.

The error is the failure to list on the face of the above-identified patent International Application No. PCT/US87/00423 filed March 2, 1987 from which priority was claimed. The failure to list International Application No. PCT/US87/00423 and the acknowledged the priority claim thereto on the face of the above-identified patent occurred through the fault of the United States Patent and Trademark Office (See, the reference to the international application and priority claim thereto on the filing receipts for the U. S. Application that issued as the above patent, copies of which are attached). A copy of the relevant assignment documents are also attached hereto confirms that Pfizer Inc. is the assignee of 100% interest in the patent.

Because the error described above was the fault of the United States Patent and Trademark Office and, thus, correction thereof is under 37 C.F.R. §1.322, it is believed that no fee is due for issuance of the Certificate of Correction. However, if any fee is required under 37 C.F.R. §1.20, authorization is provided to charge the appropriate fee to Pfizer Deposit Account No. 16-1445. Two

APPROVED

APR 12 2001
FOR THE DIRECTOR OF USPTO

PUBLISH

REVIEW

TCI

copies of this letter are enclosed.

Respectfully submitted,

Dated:

February 28, 2001

Paul H. Ginsburg
PAUL H. GINSBURG
ATTORNEY for Applicants
Reg. No. 28,718

Pfizer Inc.
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 573-**2369**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 4,831,031

DATED : May 16, 1987

INVENTOR(S) : John A. Lowe, III, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

On the first page, left column, the patent should state that U.S. Application Serial No. 07/146,886, filed January 22, 1988 is a continuation-in-part of PCT No. PCT/US87/00423 filed March 2, 1997.

MAILING ADDRESS OF SENDER:

Pfizer Inc.
Patent Department
235 East 42nd Street
New York, NY 10017-5755

PATENT NO. 4,831,031

No. of additional copies

Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 4,831,013
DATED : May 16, 1989
INVENTOR(S) : John E. Francis

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims:

In claim 12, column 30, line 3, delete "piperideine"

In claim 14, column 30, line 13, "1,2,5,6-tetrahydropyridine" should read ---1,2,5,6-tetrahydropyridine---.

In claim 18, column 31, line 1, after "substituent", insert ---selected---.

In claim 25, column 31, line 66, delete "is" (first occurrence)

In claim 27, column 32, line 10-11, delete "carboxy lower alkyl".

In claim 37, column 32, line 63, "5,6-dihydro-2-(2-furyl)-5-imino-pyrido[4,3,-e][1,2,4]1" should read:
---5,6-dihydro-2-(2-furyl)-5-imino-pyrido [4,3,-e][1,2,4]- ---.

Signed and Sealed this
Eighth Day of May, 1990

Attest:

HARRY F. MANBECK, JR.

Attesting Officer

Commissioner of Patents and Trademarks